|
- Endo - Home | Introducing Keenova and Par Health
Mallinckrodt and Endo are merging to create a leading global therapeutics company with branded and generic products Stay tuned for updates
- Mallinckrodt and Endo to Combine to Create a Global, Scaled . . .
Mallinckrodt and Endo plan to combine their generic pharmaceuticals businesses and Endo's sterile injectables business after the close of the transaction and intend to separate that business from the combined company at a later date
- Mallinckrodt, Endo Announce Planned Leadership Team for Merged Company
Mallinckrodt and Endo commenced mailing of the definitive joint proxy statement prospectus to shareholders of Mallinckrodt and Endo, respectively, on or about May 12, 2025
- Investors | Endo - Overview
Mallinckrodt and Endo have merged to create a global, scaled, diversified therapeutics leader Visit our new Investor Relations website at ir mallinckrodt com for up-to-date investor relations information and subscribe to email alerts
- Mallinckrodt and Endo Announce Significant Progress in Proposed Merger
As announced on March 13, 2025, the proposed Mallinckrodt and Endo transaction envisions the spin-off of the combined generic pharmaceuticals businesses and Endo's sterile injectables business into a new standalone entity separate from the remaining branded pharmaceuticals business
- Investors | Endo - Press Releases
Goldman Sachs Co LLC served as Endo's financial advisor; Davis Polk Wardwell LLP served as Endo's lead counsel; and Paul, Weiss, Rifkind, Wharton Garrison LLP and A L Goodbody LLP also served as legal counsel to Endo
- Investors | Endo - Press Releases
Endo, a wholly-owned subsidiary of Mallinckrodt plc, announced today that two presentations related to plantar fibromatosis (PFI) and plantar fasciitis (PFA) will be shared during the American
- Endo Completes International Pharmaceuticals Business Divestiture
Endo is a diversified pharmaceutical company boldly transforming insights into life-enhancing therapies Our passionate team members collaborate to develop and deliver these essential medicines
|
|
|